Form 4: Septerna Executive Sells Shares
Insider Transaction (Form 4)
Daniel D. Long, SVP, Drug Discovery of Septerna, Inc., sold 3,333 shares of common stock on September 1, 2026 for $37.83 per share.
Summary
- Option exercise/conversion: acquired 3,333 Common Stock at $2.76 ($9,199) on September 1, 2026; holds 99,745 after (Direct).
- Open-market sale: disposed of 3,333 Common Stock at $37.83 ($126,078) on September 1, 2026; holds 96,412 after (Direct).
- Option exercise/conversion: disposed of 3,333 Stock Option (Right to Buy) on September 1, 2026; holds 9,085 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $126,078 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Daniel D. Long — Officer (SVP, Drug Discovery)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Option exercise/conversion | Common Stock | 3,333 | $3 | $9.2K | 99,745 |
| 2026-09-01 | Open-market sale | Common Stock | 3,333 | $38 | $126.1K | 96,412 |
| 2026-09-01 | Option exercise/conversion | Stock Option (Right to Buy) | 3,333 | — | — | 9,085 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Option exercise/conversion (3,333 shares) |
| 2026-09-01 | Open-market sale (3,333 shares) |
| 2026-09-01 | Option exercise/conversion (3,333 shares) |
Keywords
insider transaction, Form 4, SEPN, Septerna, Inc., bearish, Daniel D. Long
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.